Relevance of Epidermal Growth Factor Receptor Genomic Gain in Predicting Clinical Response to Kinase Inhibitors in Non-Small-Cell Lung Cancer

Clin Lung Cancer. 2005 Nov;7(3):163-5. doi: 10.1016/S1525-7304(11)70404-1.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride
  • Gefitinib
  • Gene Dosage*
  • Genes, erbB-1*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / mortality
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / therapeutic use

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Gefitinib